Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

FENC 11.13.2024

Full Press ReleaseSEC FilingsOur FENC Tweets

About Gravity Analytica

Recent News

  • 12.20.2024 - FENNEC PHARMACEUTICALS ANNOUNCES PEDMARQSI POSITIVE RECOMMENDATION BY NICE FOR THE PREVENTION OF CISPLATIN-INDUCED HEARING LOSS IN ENGLAND AND WALES
  • 12.20.2024 - Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
  • 12.19.2024 - FENNEC PHARMACEUTICALS ANNOUNCES EARLY PARTIAL REPAYMENT OF ITS OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT

Recent Filings

  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.06.2025 - 144 Report of proposed sale of securities
  • 12.20.2024 - EX-99.1 EX-99.1

RESEARCH TRIANGLE PARK, N.C.,Nov. 13, 2024(GLOBE NEWSWIRE) --Fennec Pharmaceuticals Inc.(NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th AnnualCraig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event.

Conference Details:

Event:15th AnnualCraig-Hallum Alpha Select ConferenceDate:November 19, 2024Location:Sheraton New York Times Square Hotel,New York City

About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visitwww.fennecpharma.com.

For further information, please contact:

Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299

Corporate & Media:Lindsay RoccoElixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Primary Logo

Source: Fennec Pharmaceuticals Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com